Table 2.

Primary and key secondary outcomes for randomized patients

COVID ordinal scale at 14 d	Results
Results of primary ordinal regression model
OR for a less favorable COVID ordinal outcome at 14 d in hydroxychloroquine arm compared with the azithromycin arm (95% credible interval)*	1.07 (0.63–1.83)*
Posterior probabilities from primary ordinal regression model for 14-d COVID ordinal outcome
P1 = Pr(OR < 1) (any benefit of hydroxychloroquine over azithromycin)	0.40
P2 = Pr(OR < 1/1.25) (at least moderate benefit of hydroxychloroquine over azithromycin)	0.14
P3 = Pr(OR > 1) (any benefit of azithromycin over hydroxychloroquine)	0.60
P4 = Pr(OR > 1.25) (at least moderate benefit of azithromycin over hydroxychloroquine)	0.29
P5 = Pr(1/1.2 < OR <1.2) (negligible difference between the two agents)	0.48
Key secondary endpoints, OR (95% credible interval)
COVID ordinal scale at 7 d	1.16 (0.68–1.96)*
Hospital-free days at 28 d	0.91 (0.54–1.54)†
ICU-free days at 28 d	0.85 (0.50–1.46)†
28-d mortality	Too few events

Definition of abbreviations: COVID = coronavirus disease; ICU = intensive care unit; OR = odds ratio; Pr = probability.

^*An OR >1 favors azithromycin over hydroxychloroquine for this comparison.

^†An OR <1 favors azithromycin over hydroxychloroquine for this comparison.